Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

July 8, 2013 8 July, 2013

Sernova Receives Patent Allowance for Therapeutic Immune Privileged Cell Technologies

LONDON, ONTARIO (Marketwire - July 9, 2013) - Sernova Corp (TSX-V: SVA), today announced the Japan Patent Office has issued a Notice of Patent Allowance to Sernova for a patent entitled "The production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells."

When transplanted into a recipient, Sertoli cells provide an immune privileged environment for therapeutic cells without the need for anti-rejection drugs. The claims of this patent relate to Sertoli cells themselves which can release factors in the body to treat a range of chronic diseases such as diabetes, Parkinson's disease, various cancers, hemophilia B and other blood diseases.

"This patent allowance further strengthens Sernova's intellectual property position and provides Sernova with the unique ability to use cells with therapeutic capabilities that are also naturally protected from immune system attack," stated Dr. Philip Toleikis, Sernova's President and CEO. "We envision our Cell Pouch(TM) transplanted with these immune privileged Sertoli cells and releasing the correct replacement factor for the treatment of a variety of diseases, without the need for anti-rejection medications. We believe such a product would be a significant advancement in the cell-based treatment of deficiency diseases."

Sernova's medical collaborators have presented evidence at leading scientific conferences demonstrating that the Cell Pouch(TM) is a safe and effective platform for the delivery of factors such as insulin from therapeutic cells. Sernova is developing the Cell Pouch(TM) as an enabling platform to treat multiple chronic debilitating diseases with immune protected, therapeutic cells and is currently evaluating the safety and efficacy of the Cell Pouch(TM) in human clinical trials for diabetes.

About Sertoli Cells

Sertoli cells release protective factors that can provide a non-toxic, immune-protected environment potentially eliminating the need for daily anti-rejection drugs that currently must be used by patients with transplanted tissues and organs. Production of therapeutic factors from the Sertoli cells would provide a means to treat disease without the concern of immune destruction of the transplanted therapeutic cells.

As part of its local immune protection Sertoli development process with therapeutic cells, Sernova is currently conducting preclinical studies to optimize Sertoli cells and islets within the Cell Pouch(TM) through a NRC-IRAP contribution agreement provided by the Government of Canada.

About Sernova

Sernova Corp is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System(TM) to provide a safe and efficacious environment for therapeutic cells and Sertolin(TM), a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs. Sernova's first cell therapy application is for insulin-dependent diabetes to reduce or eliminate the need for insulin injections.

For further information contact: Philip Toleikis, Ph.D., President and CEO Tel: (604) 961-2939

Tony Russo, Ph.D. Russo Partners, LLC Tel: (212) 845-4251

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward- looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.